Saturday, April 27, 2024 4/27/2024

Development of completely automated quality control procedures for 4 PET Imaging tracers that will increase production throughput and lead to expanded diversity of PET imaging available to patients.

Award Number: R44MH119110
ORGANIZATION: NATIONAL INSTITUTE OF MENTAL HEALTH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

Long-term objective of this project is increased availability of Positron Emission Tomography (PET) imaging to patients across different disease areas. The approach focuses on eliminating complexity and quality risks associated with production of radioactive contrast agents, PET tracers relied upon in neurology and oncology. The specific solution developed in this project is a platform that will afterwards deliver the same benefits in production of PET tracers used in an expanded variety of disease areas. PET Tracers rely on radionuclides with inherently short half-lives such as F-18 (110 min), Ga-68 (68 min), that have to be produced multiple times a day from a cyclotron or generator. Quality Control (QC) of PET tracers is by far the most labor-, skill- and risk-intensive part of the cGMP production process. It requires assessment of 10-14 different parameters for the PET tracer to be released for patient use. The complex current state of PET tracer QC presents a barrier to the expansion of PET imaging, particularly to smaller hospitals and clinics in the rural US, often limits the number of PET tracers that may be produced in one facility, and ultimately limits the availability of PET imaging to patients. The innovation is in the disposable kit that enables multiple tests from a single sample on a single platform composed of a microplate reader and automated pipettor. Tracer-QC has been successfully benchmarked with FDG, the most common PET tracer used in multiple applications. It has delivered the desired simplification, efficiency and traceability of data. Four PET tracers chosen for this project are: [F- 18]Florbetaben – FDA approved PET tracer for amyloid imaging in Alzheimer’s Disease diagnostics, [F- 18]Flortaucipir, – a tau protein marker with highest predictive potential for Alzheimer’s Disease and other neurodegenerative diseases such as TBI/CTE, [F-18]FMISO – leading marker for detection and management of sarcomas, [Ga-68]DOTATATE – FDA-approved PET tracer for neuroendocrine tumors. The impacts of this work will be: (1) improved availability of these 4 PET tracers to patients, (2) streamlined procedures for transition of future tracers onto Tracer-QC platform, and (3) freed up capacity in PET production facilities to add more PET tracers to their offerings to the imaging centers. Each Phase I Specific Aim focuses on one of 2 riskiest new tests. Milestone is experimental demonstration of the desired limit of detection. Specific Aim 1: Acetone (LOD = 2000 ppm). Specific Aim 2: DMSO (LOD = 2000 ppm). Phase II Specific Aims 1-4: Clinical Production of new tracer using Tracer-QC for quality control. 1 ([F-18]Florbetaben, 2 ([F-18]Flortaucipir, 3 ([F-18]FMISO), 4 ([Ga- 68]DOTATATE): Milestones are (a) Tracer-QC method validated for each PET tracer QC and (b) IND/NDA amendment filed. The project will yield a fully-automated QC solution that has been validated, de-risked and is positioned for easy implementation with DMF cross-reference for 4 new tracers.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2020	TRACE-ABILITY INC	6919B WOODLEY AVE	VAN NUYS	CA	91406	LOS ANGELES	USA	Mental Health Research Grants	000	3	3/4/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2020	TRACE-ABILITY, INC.	6919B WOODLEY AVE	VAN NUYS	CA	91406	LOS ANGELES	USA	Mental Health Research Grants	000	3	6/2/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $810,570 )
2020	2020	TRACE-ABILITY, INC.	6919B WOODLEY AVE	VAN NUYS	CA	91406	LOS ANGELES	USA	Mental Health Research Grants	002	3	7/9/2020	NON-COMPETING CONTINUATION	$810,570
2020	2019	TRACE-ABILITY, INC.	6919B WOODLEY AVE	VAN NUYS	CA	91406	LOS ANGELES	USA	Mental Health Research Grants	001	2	1/6/2020	EXTENSION WITH OR WITHOUT FUNDS	$0
2020	2018	TRACE-ABILITY, INC.	6919B WOODLEY AVE	VAN NUYS	CA	91406	LOS ANGELES	USA	Mental Health Research Grants	000	1	12/27/2019	NEW	$0
														Subtotal = $810,570

Issue Date FY: 2019 ( Subtotal = $689,910 )
2019	2019	TRACE-ABILITY, INC.	6919B WOODLEY AVE	VAN NUYS	CA	91406	LOS ANGELES	USA	Mental Health Research Grants	000	2	7/25/2019	EXTENSION WITH OR WITHOUT FUNDS	$689,910
														Subtotal = $689,910

Issue Date FY: 2018 ( Subtotal = $232,454 )
2018	2018	TRACE-ABILITY, INC.	6160 BRISTOL PKWY STE 200	CULVER CITY	CA	90230	LOS ANGELES	USA	Mental Health Research Grants	000	1	8/8/2018	NEW	$232,454
2018	2018	TRACE-ABILITY, INC.	6160 BRISTOL PKWY STE 200	CULVER CITY	CA	90230	LOS ANGELES	USA	Mental Health Research Grants	001	1	8/13/2018	NEW	$0
														Subtotal = $232,454

Grand Total All Awards = $1,732,934

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of completely automated quality control procedures for 4 PET Imaging tracers that will increase production throughput and lead to expanded diversity of PET imaging available to patients.

Award Number: R44MH119110

ORGANIZATION: NATIONAL INSTITUTE OF MENTAL HEALTH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer